Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: Celgene The Latest To Buy Into Nimbus’ Computational Chemistry Approach

Executive Summary

The big biotech takes options on preclinical Tyk2 and STING programs. REGENXBIO drops out of the bidding for Dimension, ceding to Ultragenyx, and Eisai licenses four drugs to Uruguay’s Grupo Biotoscana.

Advertisement

Related Content

Early-Stage Cell And Gene Therapy Progress: Updates From Casebia, BlueRock, Athersys, Cynata
Bristol Engineers An Oral TYK2 Inhibitor With Biologic-Like Efficacy That Rivals JAK Safety
Finance Watch: Pfizer Ventures' Dalton Makes Sense Of Neuroscience Focus Within New $600m VC Fund Commitment
Celgene's Terrie Curran On Building, Broadening The I&I Franchise
Endocyte's ABX Deal To Serve As Springboard For Radioligand Pipeline
Arcturus Enters Reverse-Merger With Alcobra To Push Differentiated RNA Approach
Merck KGaA Rules Out Major M&A, Says MS Pill Mavenclad Will Be Major Earner
Allergan's Tribe Deal Over Restasis Sparks Ire From Legislators
Deal Watch: Are Ultragenyx, REGENXBIO In A Bidding War For Dimension?
Profile: Katherine Bowdish, Sanofi’s Early Science Investment Scout

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC099603

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel